Monthly Archives: September 2015
Testing and Toxicology of Designer Drugs
This article explains Testing and Toxicology of Designer Drugs and the scientific, legal or practical evidence readers should understand.
This article explains Testing and Toxicology of Designer Drugs and the scientific, legal or practical evidence readers should understand.
A decision model can show which assumptions most affect estimated costs. McCrone and colleagues used such a model to compare psilocybin-assisted therapy with medication, cognitive behavioral therapy, and their combination for severe depression. What the model projected The model simulated response, remission, and relapse over six months using inputs from…
Read Article: Which Assumptions Drove a Psilocybin Cost-Effectiveness Model?
Psilocybin-assisted therapy trials can combine the drug with different forms of psychological support. Chen and colleagues asked whether the support protocol was associated with differences in depressive symptoms across studies. What the review compared The analysis included 10 eligible studies with 515 adults. The authors classified the protocols by whether…
A network meta-analysis can compare treatments studied in different trials, but its estimates depend on how the trials are connected. Hsu and colleagues examined whether using a different placebo benchmark changed the estimated effect of psilocybin on depressive symptoms. Why distinguish the placebo groups? The researchers pooled randomized trials involving…
Read Article: Why Did the Placebo Benchmark Change the Estimated Psilocybin Effect?